NEW YORK, May 31 - Aventis Pharma and chemical microarray developer Graffinity Pharmaceutical Design have signed a collaboration to identify leads for Aventis' drug targets, the two companies said Thursday. 

Financial details were not disclosed.

Graffinity, based in Heidelberg, Germany, has developed small-molecule microarrays that identify which compounds bind favorably with a protein drug target.